Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07086755 · ClinicalTrials.gov registry record · Phase 2
Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury
A Phase 2 study of Nonintubated Acute Respiratory Distress Syndrome (ARDS) and Pathogen-associated Lung Injury, sponsored by Bentley J. Bobrow.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,100
- Enrollment target
- 1
- Study location
NCT07086755: Recruiting Phase 2 study of Nonintubated Acute Respiratory Distress Syndrome (ARDS) and Pathogen-associated Lung Injury, sponsored by Bentley J. Bobrow.
NCT07086755 is a Phase 2 study of Nonintubated Acute Respiratory Distress Syndrome (ARDS) and Pathogen-associated Lung Injury that is actively recruiting participants, run by Bentley J. Bobrow. The registered enrollment target is 1,100 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (727% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07086755, a Phase 2 study of Nonintubated Acute Respiratory Distress Syndrome (ARDS) and Pathogen-associated Lung Injury, is actively recruiting participants, sponsored by Bentley J. Bobrow.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,100 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.
Primary Outcome
The primary outcome is a hierarchical composite endpoint with 3 components: Death (yes or no); Duration of mechanical ventilation (MV) or extracorporeal membrane oxygenation (ECMO) in days; and Duration of high-flow nasal oxygenation (HFNO) or noninvasive ventilation (NIV) in days. Data will be reported as a Win Ratio, which quantifies the relative benefit of treatment compared to control. The Win Ratio is calculated from all pairwise comparisons of each patient in the treatment group compared w
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vadadustat 900mg
- DRUG Vadadustat 1200mg
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2025-10-23 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
What NCT07086755 shows while recruiting
NCT07086755 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (727% higher).
The record links to 2 conditions, with Nonintubated Acute Respiratory Distress Syndrome (ARDS) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07086755 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07086755 about?
NCT07086755 is a clinical study titled "Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury". The objective of this study is to assess the efficacy and safety of vadadustat for treating hospitalized patients with nonintubated Acute Respiratory Distress Syndrome (ARDS) secondary to pathogen-associated lung injury.
What is the current status of trial NCT07086755?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,100 participants. The study started on 2025-10-23. Estimated completion is 2026-07-01.
What conditions does trial NCT07086755 study?
This clinical trial studies the following conditions: Nonintubated Acute Respiratory Distress Syndrome (ARDS), Pathogen-associated Lung Injury.
What interventions are being tested in trial NCT07086755?
The interventions under investigation include: Placebo (DRUG), Vadadustat 900mg (DRUG), Vadadustat 1200mg (DRUG).
Who is sponsoring clinical trial NCT07086755?
This trial is sponsored by Bentley J. Bobrow, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07086755 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07086755's enrollment target sits among peer trials
1,100 21st of 2000 higher than 1,979 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI